Le Lézard
Classified in: Science and technology
Subject: Product/Service

Zuora Announces New Asia-Pacific Data Center


Zuora, Inc. (NYSE: ZUO), a leading monetization suite for modern business, today announced its new data center in Japan is now live to support customers in the Asia-Pacific (APAC) region. The new data center provides Zuora customers in APAC with a regional option for data locality requirements and improved in-region product performance.

Zuora has a strong presence in APAC, with more than 100 customers in the region, including BIGLOBE, one of Japan's leading internet service providers. Japan represents the company's third-largest market by annual recurring revenue (ARR) and second largest by total addressable market (TAM), while Australia is the company's sixth-largest market by ARR.

The APAC data center provides:

"Zuora's new data center reinforces our commitment to our APAC customers while unlocking growth opportunities in this critical, innovative market," said Pete Hirsch, Chief Product and Technology Officer at Zuora. "We are excited to help companies in the region monetize new revenue streams faster and more securely, with an even better customer experience."

To learn more, visit zuora.com.

About Zuora, Inc.

Zuora provides a leading monetization suite to build, run and grow a modern business through a dynamic mix of usage-based models, subscription bundles and everything in between. From pricing and packaging, to billing, payments and revenue accounting, Zuora's flexible, modular software platform is designed to help companies evolve monetization strategies with customer demand. More than 1,000 customers around the world, including BMC Software, Box, Caterpillar, General Motors, The New York Times, Schneider Electric and Zoom use Zuora's leading combination of technology and expertise to turn recurring relationships and recurring revenue into recurring growth. Zuora is headquartered in Silicon Valley with offices in the Americas, EMEA and APAC. To learn more, please visit zuora.com.

Forward-Looking Statements

This press release may be deemed to contain forward-looking statements. Words such as "plan," "expect" and "will" and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements involve risks and uncertainties. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release.

Information on these risks and additional risks and uncertainties that could cause actual outcomes and results to differ materially from those included in or contemplated by the forward-looking statements contained in this release is included under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended January 31, 2024 and the Quarterly Report on Form 10-Q for the most recent fiscal quarter, which is available on the "Investors" page of our website at https://investor.zuora.com and on the U.S. Securities and Exchange Commission's website at www.sec.gov. Additional information will also be set forth in other documents that we may file from time to time with the Securities and Exchange Commission. All forward-looking statements contained herein are based on information available to us as of the date hereof. Except to the extent required by law, we do not assume any obligation to update these statements as a result of new information, future events, or otherwise.

© 2024 Zuora, Inc. All Rights Reserved. Third party trademarks mentioned above are owned by their respective companies. Nothing in this press release should be construed to the contrary, or as an approval, endorsement or sponsorship by any third parties of Zuora, Inc. or any aspect of this press release.

SOURCE: ZUORA, INC.


These press releases may also interest you

at 15:30
Anthony "Tony" Van Heugten, the Chief Technology...

at 15:05
Merck , known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck's investigational antibody drug conjugate (ADC) that targets...

at 15:00
AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental...

at 12:55
Vertex Pharmaceuticals Incorporated today announced longer-term data for CASGEVYtm (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the...

at 12:35
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...

at 12:35
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab),...



News published on and distributed by: